• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Organon & Co.

    6/13/25 4:56:51 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGN alert in real time by email
    S-8 1 tm2517792d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 13, 2025 

    Registration No. 333- 

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, DC 20549

     

    FORM S-8 

    REGISTRATION STATEMENT 

    UNDER 

    THE SECURITIES ACT OF 1933

     

    ORGANON & CO. 

    (Exact name of registrant as specified in its charter)

     

    Delaware  46-4838035 
    (State or other jurisdiction of  (I.R.S. Employer 
    incorporation or organization)  Identification Number)

     

    30 Hudson Street, Floor 33
    Jersey City, NJ 07302 

    (551) 430-6900 

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Organon & Co. 2021 Incentive Stock Plan, as Amended 

    (Full title of the plan)

     

    Kirke Weaver
    General Counsel and Corporate Secretary
    30 Hudson Street, Floor 33
    Jersey City, NJ 07302
    (551) 430-6900 

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   x   Accelerated filer   ¨
           
    Non-accelerated filer   ¨   Smaller reporting company   ¨
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    In accordance with General Instruction E to Form S-8, this registration statement incorporates by reference the contents of the Registration Statement (No. 333-256757) on Form S-8 (the “Original Registration Statement”) filed by Organon & Co. (the “Company”) on June 3, 2021 relating to the offer, issuance, and/or sale of common stock, par value $0.01 per share (the “Common Stock”) under the Organon & Co. 2021 Incentive Stock Plan (as amended, the “Plan”). This registration statement is being filed to register an additional 7,800,000 shares of Common Stock available for issuance under the Plan. In accordance with General Instruction E to Form S-8, this registration statement consists only of the following: the facing page; this page; required opinions and consents; the signature page; and the additional information required in this registration statement that was not in the Original Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.Incorporation of Documents by Reference.

     

    The following documents filed by the Company with the Securities and Exchange Commission (the “Commission”), are incorporated by reference herein and shall be deemed to be a part hereof:

     

    a)the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on February 28, 2025;

     

    b)the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, filed on May 2, 2025;

     

    c)the Company’s Current Reports on Form 8-K, filed on January 21, 2025, April 15, 2025, May 1, 2025, and May 27, 2025.

     

    d)the portions of the Definitive Proxy Statement on Schedule 14A for the 2025 Annual Meeting of Stockholders, filed on April 25, 2025, incorporated by reference into the Annual Report on Form 10-K for the year ended December 31, 2024; and

     

    e)the description of the Common Stock contained in the Company’s Information Statement, filed as Exhibit 99.1 to the Registrant’s Registration Statement on Form 10 (File No. 001-40235), under the heading “Description of Capital Stock”, including any amendments or reports filed for purposes of updating such description, including Exhibit 4.2 to the Company’s Annual Report on Form 10-K (File No. 001-40235), filed on March 21, 2022, including any amendment or report filed for the purpose of updating such description.

     

    In addition, all documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, but prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary in such filing, none of the information that the Company discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise be included in, or deemed to be a part of, this Registration Statement.

     

    Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

    Item 8. Exhibits.

     

    Exhibit
    No.

      Exhibit Description
       
    5.1*   Opinion of Kirke Weaver, General Counsel and Corporate Secretary of the Company
         
    10.1   Organon  & Co. 2021 Incentive Stock Plan (incorporated by reference to Exhibit 10.16 to the Company’s Current Report on Form 8-K filed on June 3, 2021)
         
    10.2   Amended and Restated Organon & Co. 2021 Incentive Stock Plan (incorporated by reference to the Company’s Definitive Proxy Statement on Schedule 14A, filed on April 25, 2025)
         
    23.1*   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
         
    23.2*   Consent of Kirke Weaver, General Counsel and Corporate Secretary of the Company (included in Exhibit 5.1)
         
    24.1*   Powers of Attorney (included on the signature page of this Registration Statement)
         
    107.1*   Filing Fee Tables

     

    *            Filed herewith.

     

    Item 9.Undertakings

     

    The undersigned registrant hereby undertakes:

     

    1.(a) To file, during any period in which offers or sales are being made, a post-effective amendment of this registration statement:

     

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);

     

    (ii)To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective registration statement;

     

    (iii)to include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

     

    provided, however, that the undertakings set forth in paragraphs (1)(a)(i) and (1)(a)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

    (b)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

     

     

    2.That, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3.Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel, the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Jersey City, New Jersey, on June 13, 2025.

     

      Organon & Co.
         
      By:

    /s/ Matthew Walsh

      Name: Matthew Walsh
      Title: Chief Financial Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin Ali, Matthew Walsh and Kirke Weaver, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and any registration statement relating to the offering covered by this registration statement and filed pursuant to Rule 462 under the Securities Act, and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully so or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, the following persons have signed this registration statement in the capacities and on the date(s) indicated.

     

    Signature   Title   Date

    /s/ Kevin Ali

    Kevin Ali

     

    Chief Executive Officer and Director

    (Principal Executive Officer)

      June 13, 2025
             

    /s/ Matthew Walsh

    Matthew Walsh

     

    Executive Vice President and Chief Financial Officer

    (Principal Financial and Accounting Officer)

      June 13, 2025
             

    /s/ Carrie Cox

    Carrie Cox

      Chair of the Board   June 13, 2025
             

    /s/ Robert Essner

    Robert Essner

      Director   June 13, 2025
             

    /s/ R. Alan Ezekowitz

    R. Alan Ezekowitz

      Director   June 13, 2025
             

    /s/ Helene D. Gayle

    Helene D. Gayle

      Director   June 13, 2025
             

    /s/ Rochelle B. Lazarus

    Rochelle B. Lazarus

      Director   June 13, 2025
             

    /s/ Deborah R. Leone

    Deborah R. Leone

      Director   June 13, 2025
             

    /s/ Phillip Ozuah

    Phillip Ozuah

      Director   June 13, 2025
             

    /s/ Cynthia M. Patton

    Cynthia M. Patton

      Director   June 13, 2025
             

    /s/ Grace Puma

    Grace Puma

      Director   June 13, 2025
             

    /s/ Shalini Sharp

    Shalini Sharp

      Director   June 13, 2025

     

     

     

    Get the next $OGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGN

    DatePrice TargetRatingAnalyst
    5/2/2025Outperform → In-line
    Evercore ISI
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    11/3/2023$33.00 → $16.00Buy → Neutral
    Goldman
    9/21/2023$28.00Overweight
    Barclays
    3/16/2023$33.00Outperform
    Raymond James
    10/14/2022$27.00 → $25.00Neutral → Underperform
    BofA Securities
    9/6/2022$37.00 → $34.00Neutral → Overweight
    Piper Sandler
    8/5/2022$40.00 → $37.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $OGN
    SEC Filings

    View All

    SEC Form 10-Q filed by Organon & Co.

    10-Q - Organon & Co. (0001821825) (Filer)

    8/6/25 8:43:01 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Organon & Co. (0001821825) (Filer)

    8/5/25 7:44:59 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Organon & Co.

    S-8 - Organon & Co. (0001821825) (Filer)

    6/13/25 4:56:51 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Organon downgraded by Evercore ISI

    Evercore ISI downgraded Organon from Outperform to In-line

    5/2/25 8:13:50 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by JP Morgan with a new price target

    JP Morgan downgraded Organon from Neutral to Underweight and set a new price target of $20.00 from $18.00 previously

    9/6/24 7:47:49 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by Goldman with a new price target

    Goldman downgraded Organon from Buy to Neutral and set a new price target of $16.00 from $33.00 previously

    11/3/23 7:22:32 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Head of R&D & CMO Arjona Ferreira Juan Camilo covered exercise/tax liability with 4,122 shares and converted options into 11,519 shares, increasing direct ownership by 43% to 24,777 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    8/12/25 4:05:37 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sequeira Ramona

    4 - Organon & Co. (0001821825) (Issuer)

    7/2/25 4:46:01 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Sequeira Ramona claimed ownership of 100 shares (SEC Form 3)

    3 - Organon & Co. (0001821825) (Issuer)

    7/2/25 4:43:54 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organon Reports Results for the Second Quarter Ended June 30, 2025

    Second quarter 2025 revenue of $1.594 billion Second quarter 2025 diluted earnings per share of $0.56 and non-GAAP Adjusted diluted earnings per share of $1.00; GAAP diluted earnings per share includes a $46 million gain, or $0.14 per share, for early extinguishment of debt Second quarter 2025 net income of $145 million and Adjusted EBITDA (non-GAAP) of $522 million, representing an Adjusted EBITDA margin of 32.7% The company repaid $345 million of long-term debt during the quarter; on track to achieve a net debt to Adjusted EBITDA ratio of less than 4.0x by year-end Revenue guidance range for full year 2025 raised to $6.275 billion to $6.375 billion based on the company's curr

    8/5/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

    Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its second quarter 2025 financial results on August 5, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. Accessing Second Quarter 2025 Financial Results Webcast Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company's website. Institutional investors and analysts interested in participating in the call may join by dialing (888) 596-4144

    7/22/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

    The American Academy of Dermatology (AAD) provides a strong evidence-based recommendation for the use of VTAMA cream in adults with moderate to severe atopic dermatitis (AD), the most common form of eczema. Recommendation reflects VTAMA cream's proven efficacy, safety, and tolerability as a steroid-free, topical aryl hydrocarbon receptor agonist. AD impacts 26 million people in the United States, 16.5 million of which are adults. Organon (NYSE:OGN), a global independent healthcare company with a focus on women's health, today announced that VTAMA® (tapinarof) cream, 1%, was granted a strong recommendation by the American Academy of Dermatology (AAD) in their 2025 focused guideline

    7/7/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/15/25 4:09:09 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Human Resources Officer Falcione Aaron bought $48,235 worth of shares (5,500 units at $8.77), increasing direct ownership by 10% to 62,974 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/7/25 12:13:47 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gen. Counsel & Corp. Secy. Weaver Kirke bought $74,054 worth of shares (8,045 units at $9.21), increasing direct ownership by 18% to 52,489 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/7/25 12:12:22 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Financials

    Live finance-specific insights

    View All

    Organon Reports Results for the Second Quarter Ended June 30, 2025

    Second quarter 2025 revenue of $1.594 billion Second quarter 2025 diluted earnings per share of $0.56 and non-GAAP Adjusted diluted earnings per share of $1.00; GAAP diluted earnings per share includes a $46 million gain, or $0.14 per share, for early extinguishment of debt Second quarter 2025 net income of $145 million and Adjusted EBITDA (non-GAAP) of $522 million, representing an Adjusted EBITDA margin of 32.7% The company repaid $345 million of long-term debt during the quarter; on track to achieve a net debt to Adjusted EBITDA ratio of less than 4.0x by year-end Revenue guidance range for full year 2025 raised to $6.275 billion to $6.375 billion based on the company's curr

    8/5/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

    Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its second quarter 2025 financial results on August 5, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. Accessing Second Quarter 2025 Financial Results Webcast Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company's website. Institutional investors and analysts interested in participating in the call may join by dialing (888) 596-4144

    7/22/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Reports Results for the First Quarter Ended March 31, 2025

    Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs in 2025 Vtama on track to achieve $150 million revenue target for full year 2025; double-digit growth in Nexplanon in the first quarter Company resets capital allocation priorities to accelerate progress towards deleveraging; new annual regular dividend rate of $0.08 per share First quarter 2025 revenue of $1.513 billion, down 7% as-reported and down 4% at constant currency, consistent with company's expectation

    5/1/25 7:00:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Leadership Updates

    Live Leadership Updates

    View All

    Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

    Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

    4/15/25 5:00:00 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

    Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel

    3/10/25 12:01:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

    Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women's health. KIRKLAND, QC, Oct. 8, 2024 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced updates to its Canadian leadership team with an appointment and promotion. Effective September 1, 2024, Jeffrey Malawsk

    10/8/24 8:01:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    2/13/24 5:12:22 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    2/5/24 3:47:19 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    1/25/24 12:23:52 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care